Completed PHASE1 INTERVENTIONAL 1-arm NCT03756818

TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors

A Phase I Study of TAK-659 and Paclitaxel in Patients With Advanced Solid Tumors

Sponsor: M.D. Anderson Cancer Center

Conditions Advanced Malignant Solid Neoplasm Ovarian Carcinoma Refractory Malignant Solid Neoplasm Refractory Ovarian Carcinoma

Interventions Mivavotinib Paclitaxel Pharmacokinetic Study

Updated 9 times since 2018 Last updated: Feb 24, 2023 Started: Mar 5, 2019 Primary completion: Feb 23, 2023 Completion: Feb 23, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03756818, this PHASE1 trial focuses on Advanced Malignant Solid Neoplasm and Ovarian Carcinoma and remains completed. Sponsored by M.D. Anderson Cancer Center, it has been updated 9 times since 2019, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Mar 2023 — Jul 2024 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Jan 2022 — Mar 2023 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Jan 2021 — Jan 2022 [monthly]

Recruiting PHASE1

▶ Show 4 earlier versions

Jun 2019 — Jan 2021 [monthly]

Recruiting PHASE1
Apr 2019 — Jun 2019 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Feb 2019 — Apr 2019 [monthly]

Not Yet Recruiting PHASE1
Dec 2018 — Feb 2019 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States